EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Genetic and molecular architecture of familial hypercholesterolemia

Marianne Abifadel, Catherine Boileau iD

Journal of Internal Medicine · 2023-02 · 293 (2) · 144-165

DOI: 10.1111/joim.13577 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Internal Medicine, online erschienen am 17.10.2022. Verfasst von Marianne Abifadel und 1 weiteren Autor:innen. Beteiligte Einrichtung: UMR1148, Inserm, Hôpital Bichat-Claude Bernard, 46 rue Henri Huchard, F-75018 Paris, France. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Hyperlipoproteinemia Type II, Atherosclerosis. Die Arbeit wurde bisher 125-mal zitiert (Crossref) und nennt 203 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atherosclerotic cardiovascular disease is the leading cause of death globally. Despite its important risk of premature atherosclerosis and cardiovascular disease, familial hypercholesterolemia (FH) is still largely underdiagnosed worldwide. It is one of the most frequently inherited diseases due to mutations, for autosomal dominant forms, in either of the LDLR , APOB , and PCSK9 genes or possibly a few mutations in the APOE gene and, for the rare autosomal forms, in the LDLRAP1 gene. The discovery of the genes implicated in the disease has largely helped to improve the diagnosis and treatment of FH from the LDLR by Brown and Goldstein, as well as the introduction of statins, to PCSK9 discovery in FH by Abifadel et al., and the very rapid availability of PCSK9 inhibitors. In the last two decades, major progress has been made in clinical and genetic diagnostic tools and the therapeutic arsenal against FH. Improving prevention, diagnosis, and treatment and making them more accessible to all patients will help reduce the lifelong burden of the disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesHyperlipoproteinemia Type IIAtherosclerosisHumansProprotein Convertase 9PhenotypeMutationReceptors, LDL

Stichwörter der Autor:innen

APOBAPOELDLRPCSK9familial hypercholesterolemiagenemutationpolygenic

Substanzen

PCSK9 protein, humanProprotein Convertase 9Receptors, LDL

Autor:innen und Institutionen

  • UMR1148, Inserm, Hôpital Bichat-Claude Bernard, 46 rue Henri Huchard, F-75018 Paris, France.
  • Laboratory of Biochemistry and Molecular Therapeutics (LBTM), Faculty of Pharmacy, Pôle Technologie-Santé, Saint Joseph University of Beirut, Beirut, Lebanon.
  • Département de Génétique, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France.

ORCID-Profile: Catherine Boileau

Zitieren

APA

Abifadel, M., & Boileau, C. (2023). Genetic and molecular architecture of familial hypercholesterolemia. Journal of Internal Medicine, 293(2), 144-165. https://doi.org/10.1111/joim.13577

Vancouver

Abifadel M, Boileau C. Genetic and molecular architecture of familial hypercholesterolemia. Journal of Internal Medicine. 2023;293(2):144-165. doi:10.1111/joim.13577

BibTeX
@article{Abifadel2023,
  author = {Abifadel, Marianne and Boileau, Catherine},
  title = {Genetic and molecular architecture of familial hypercholesterolemia},
  journal = {Journal of Internal Medicine},
  year = {2023},
  volume = {293},
  number = {2},
  pages = {144--165},
  doi = {10.1111/joim.13577}
}
Kostenlos starten →